Biomarkers identified will not only help to recognize subsets of breast cancer patients likely to benefit from NIS-targeted radionuclide therapy, but may also serve as novel targets for developing strategies to selectively increase NIS-mediated radionuclide uptake in corresponding breast cancer subtypes. Here, SLC5A5 is linked to breast carcinoma.